Amgen Arrives

Langreth, Robert
January 2006
Forbes Asia;1/9/2006, Vol. 2 Issue 1, p20
The article considers the efficacy of Amgen's drug panitumumab in reducing cancer progression. In November 2006, the Thousand Oaks, California company gained big win, when a final-stage test of advanced colon cancer patients found that the drug panitumumab reduced the rate of cancer progression by 46 percent. While hardly a cure, the drug may avoid the allergic reaction sometimes seen with Erbitux, made by Bristol-Myers Squibb and Imclone Systems.


Related Articles

  • Palifermin: In Myelotoxic Therapy-Induced Oral Mucositis. Siddiqui, M. Asif A.; Wellington, Keri // Drugs;2005, Vol. 65 Issue 15, p2139 

    â–´ Palifermin, a recombinant human keratinocyte growth factor (KGF), mimics the actions of endogenous KGF and has shown efficacy in the management of myelotoxic therapy-induced oral mucositis in cancer patients. â–´ In a randomised, double-blind trial in patients with haemtaological...

  • Structure-based calculation of drug efficiency indices. Hetényi, Csaba; Maran, Uko; García-Sosa, Alfonso T.; Karelson, Mati // Bioinformatics;Oct2007, Vol. 23 Issue 20, p2678 

    Motivation: The efficiency indices (EI's) have been derived from the experimental binding affinities of drug candidates to macromolecules. These ‘two-in-one’ measures include information on both pharmacodynamics and pharmacokinetics of the candidate molecules. The time-consuming...

  • Commentary. Cheung, Amy // Evidence Based Mental Health;Feb2007, Vol. 10 Issue 1, p20 

    The author reviews the study regarding the safety of antidepressant treatment to children. He points out on a possible signal for increased risk in children and adolescents who are treated with antidepressants. He suggests that the findings should serve as a reminder to all clinicians, patients...

  • Why the AUC/MIC Ratio Should Not Be Used to Predict the Effects of b -Lactams. Mouton, Johan W. // Clinical Infectious Diseases;7/15/2002, Vol. 35 Issue 2, p209 

    Comments on an article about pharmacokinetic and pharmacodynamic (PK/PD) relationships. Application of PK/PD indices for predicting the effect of combination therapy; Influence of antibiotic area under the curve on the determination of drug effects; Analysis of drug effects.

  • Statins not linked with decreased risk for colorectal cancer. Shafer, Emily // Hem/Onc Today;7/10/2008, Vol. 9 Issue 12, p16 

    The article discusses research being done on the treatment of colorectal cancer. It references a study by D. J. Robertson et al which reveals that the use of statins does not have a relation to the development of colorectal cancer. It states that statin use was associated with a slight reduction...

  • Potential of Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine in Facilitating Enhanced Delivery of Active Drug to Interior Sites of Tumors: A Two-Tier Monolayer In Vitro Study. Tsume, Yasuhiro; Hilfinger, John; Amidon, Gordon // Pharmaceutical Research;Oct2011, Vol. 28 Issue 10, p2575 

    Purpose: To evaluate the advantages of amino acid/dipeptide monoester prodrugs for cancer treatments by assessing the uptake and cytotoxic effects of floxuridine prodrugs in a secondary cancer cell monolayer following permeation across a primary cancer cell monolayer. Methods: The first Capan-2...

  • PIII-18. Tae, Y. M.; Kim, J. R.; Lim, K. S.; Kim, J. W.; Kim, B. H.; Jeon, J. Y.; Chung, O. H.; Cho, J. Y.; Yu, K. S.; Shin, S. G.; Jang, I. J. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP63 

    Background: Voglibose is alpha-glucosidase inhibitor. Due to negligible oral absorption, measuring drug concentration in the blood is impractical. So we proposed the pharmacodynamic assessment method to reflect drug effect and this study aimed to validate this method.Methods: Placebo-controlled,...

  • Escitalopram: A Review of its Use in the Management of Major Depressive Disorder. Murdoch, David; Keam, Susan J. // Drugs;2005, Vol. 65 Issue 16, p2379 

    Escitalopram (Cipralex®, Lexapro™), the active S-enantiomer of the racemic selective serotonin reuptake inhibitor (SSRI) citalopram (RS-citalopram), is a highly selective inhibitor of the serotonin transporter protein. It possesses a rapid onset of antidepressant activity, and is an...

  • ASCO ROUNDUP.  // BioWorld Today;6/4/2008, Vol. 19 Issue 108, p6 

    The article reports on the results of Celgene Corp.'s Phase III trial of Vidaza. The results indicated that the two-year survival rate for patients receiving Vidaza, a demethylating agent, was 50.8 percent, nearly doubled the 26.2 percent for conventional care regimens. The median overall...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics